These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

143 related articles for article (PubMed ID: 38612917)

  • 1. Effect of Empagliflozin with or without the Addition of Evolocumab on HDL Subspecies in Individuals with Type 2 Diabetes Mellitus: A Post Hoc Analysis of the EXCEED-BHS3 Trial.
    Bonilha I; Gomes ÉIL; Carmo HRP; Breder I; Barreto J; Breder J; Munhoz DB; Carvalho LSF; Quinaglia T; Kimura-Medorima ST; Gossi CM; Zimetti F; Nadruz W; Zanotti I; Sposito AC;
    Int J Mol Sci; 2024 Apr; 25(7):. PubMed ID: 38612917
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Evolocumab on top of empagliflozin improves endothelial function of individuals with diabetes: randomized active-controlled trial.
    Sposito AC; Breder I; Barreto J; Breder J; Bonilha I; Lima M; Oliveira A; Wolf V; Luchiari B; do Carmo HR; Munhoz D; Oliveira D; Coelho-Filho OR; Coelho OR; Matos-Souza JR; Moura FA; de Carvalho LSF; Nadruz W; Quinaglia T; Kimura-Medorima ST;
    Cardiovasc Diabetol; 2022 Aug; 21(1):147. PubMed ID: 35933413
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Empagliflozin increases plasma levels of campesterol, a marker of cholesterol absorption, in patients with type 2 diabetes: Association with a slight increase in high-density lipoprotein cholesterol.
    Jojima T; Sakurai S; Wakamatsu S; Iijima T; Saito M; Tomaru T; Kogai T; Usui I; Aso Y
    Int J Cardiol; 2021 May; 331():243-248. PubMed ID: 33556413
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effects of evolocumab in individuals with type 2 diabetes with and without atherogenic dyslipidemia: An analysis from BANTING and BERSON.
    Lorenzatti AJ; Monsalvo ML; López JAG; Wang H; Rosenson RS
    Cardiovasc Diabetol; 2021 Apr; 20(1):94. PubMed ID: 33941192
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Rationale and design of the expanded combination of evolocumab plus empagliflozin in diabetes: EXCEED-BHS3 trial.
    Breder I; Cunha Breder J; Bonilha I; Munhoz DB; Medorima STK; Oliveira DC; do Carmo HR; Moreira C; Kontush A; Zimetti F; Zanotti I; Carvalho LSF; Nadruz W; Muscelli E; Quinaglia T; Sposito AC;
    Ther Adv Chronic Dis; 2020; 11():2040622320959248. PubMed ID: 33062236
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy and safety of evolocumab in individuals with type 2 diabetes mellitus: primary results of the randomised controlled BANTING study.
    Rosenson RS; Daviglus ML; Handelsman Y; Pozzilli P; Bays H; Monsalvo ML; Elliott-Davey M; Somaratne R; Reaven P
    Diabetologia; 2019 Jun; 62(6):948-958. PubMed ID: 30953107
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Potential contribution of haemoconcentration to changes in lipid variables with empagliflozin in patients with type 2 diabetes: A post hoc analysis of pooled data from four phase 3 randomized clinical trials.
    Lund SS; Sattar N; Salsali A; Neubacher D; Ginsberg HN
    Diabetes Obes Metab; 2021 Dec; 23(12):2763-2774. PubMed ID: 34463415
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effects of empagliflozin on lipoprotein subfractions in patients with type 2 diabetes: data from a randomized, placebo-controlled study.
    Rau M; Thiele K; Korbinian Hartmann NU; Möllmann J; Wied S; Böhm M; Scharnagl H; März W; Marx N; Lehrke M
    Atherosclerosis; 2021 Aug; 330():8-13. PubMed ID: 34218214
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Empagliflozin versus dapagliflozin in patients with type 2 diabetes inadequately controlled with metformin, glimepiride and dipeptidyl peptide 4 inhibitors: A 52-week prospective observational study.
    Ku EJ; Lee DH; Jeon HJ; Oh TK
    Diabetes Res Clin Pract; 2019 May; 151():65-73. PubMed ID: 30954510
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effects of empagliflozin on the urinary albumin-to-creatinine ratio in patients with type 2 diabetes and established cardiovascular disease: an exploratory analysis from the EMPA-REG OUTCOME randomised, placebo-controlled trial.
    Cherney DZI; Zinman B; Inzucchi SE; Koitka-Weber A; Mattheus M; von Eynatten M; Wanner C
    Lancet Diabetes Endocrinol; 2017 Aug; 5(8):610-621. PubMed ID: 28666775
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of alirocumab on individuals with type 2 diabetes, high triglycerides, and low high-density lipoprotein cholesterol.
    Colhoun HM; Leiter LA; Müller-Wieland D; Cariou B; Ray KK; Tinahones FJ; Domenger C; Letierce A; Israel M; Samuel R; Del Prato S
    Cardiovasc Diabetol; 2020 Feb; 19(1):14. PubMed ID: 32035487
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effect of empagliflozin on plasma proprotein convertase subtilisin/kexin type 9 (PCSK9) in patients with type 2 diabetes.
    Tricò D; Raggi F; Distaso M; Ferrannini E; Solini A
    Diabetes Res Clin Pract; 2022 Aug; 190():109983. PubMed ID: 35803317
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Long-term effectiveness and safety of quadruple combination therapy with empagliflozin versus dapagliflozin in patients with type 2 diabetes: 3-year prospective observational study.
    Ku EJ; Lee DH; Jeon HJ; Oh TK
    Diabetes Res Clin Pract; 2021 Dec; 182():109123. PubMed ID: 34740742
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A prospective randomized study comparing effects of empagliflozin to sitagliptin on cardiac fat accumulation, cardiac function, and cardiac metabolism in patients with early-stage type 2 diabetes: the ASSET study.
    Hiruma S; Shigiyama F; Hisatake S; Mizumura S; Shiraga N; Hori M; Ikeda T; Hirose T; Kumashiro N
    Cardiovasc Diabetol; 2021 Feb; 20(1):32. PubMed ID: 33530982
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Impact of proprotein convertase subtilisin/kexin type 9 inhibition with evolocumab on the postprandial responses of triglyceride-rich lipoproteins in type II diabetic subjects.
    Taskinen MR; Björnson E; Andersson L; Kahri J; Porthan K; Matikainen N; Söderlund S; Pietiläinen K; Hakkarainen A; Lundbom N; Nilsson R; Ståhlman M; Adiels M; Parini P; Packard C; Borén J
    J Clin Lipidol; 2020; 14(1):77-87. PubMed ID: 31917184
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Therapy of empagliflozin plus metformin on T2DM mice shows no higher amelioration for glucose and lipid metabolism than empagliflozin monotherapy.
    Wang Z; Zhou J; Lu M; Liang Y; Jiang Z; Chen K
    Life Sci; 2019 Sep; 232():116622. PubMed ID: 31271767
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparison of empagliflozin and vildagliptin for efficacy and safety in type 2 diabetes mellitus in the Pakistani population.
    Khan A; Khan IA; Abidi H; Ahmed M
    Front Endocrinol (Lausanne); 2022; 13():926633. PubMed ID: 36060955
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparison of the clinical effect of empagliflozin on glycemic and non-glycemic parameters in Japanese patients with type 2 diabetes and cardiovascular disease treated with or without baseline metformin.
    Tanaka A; Shimabukuro M; Teragawa H; Okada Y; Takamura T; Taguchi I; Toyoda S; Tomiyama H; Ueda S; Higashi Y; Node K;
    Cardiovasc Diabetol; 2021 Jul; 20(1):160. PubMed ID: 34332584
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Lipid-lowering efficacy of the PCSK9 inhibitor evolocumab (AMG 145) in patients with type 2 diabetes: a meta-analysis of individual patient data.
    Sattar N; Preiss D; Robinson JG; Djedjos CS; Elliott M; Somaratne R; Wasserman SM; Raal FJ
    Lancet Diabetes Endocrinol; 2016 May; 4(5):403-10. PubMed ID: 26868195
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effect of Evolocumab on Lipoprotein Particles.
    Toth PP; Sattar N; Blom DJ; Martin SS; Jones SR; Monsalvo ML; Elliott M; Davis M; Somaratne R; Preiss D
    Am J Cardiol; 2018 Feb; 121(3):308-314. PubMed ID: 29221604
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.